Catheter Precision, Inc. (VTAK) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Catheter Precision, Inc. is a medical technology company focused on cardiac electrophysiology (EP). Its primary commercial products are the VIVO System (non-invasive 3D cardiac mapping) and LockeT (suture retention device). The company recently formed two subsidiaries: Cardionomix (acquiring the CPNS System for heart failure treatment) and KardioNav (developing EP mapping technologies). The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Q2 2024 (3 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $212,000 | $355,000 | $93,000 | $175,000 |
| Gross Profit | $198,000 | $330,000 | $77,000 | $154,000 |
| Gross Margin | 93.4% | 93.0% | 82.8% | 88.0% |
| Operating Loss | $(4,686,000) | $(8,261,000) | $(2,717,000) | $(5,333,000) |
| Net Loss (Attributable to CP) | $(5,109,000) | $(9,154,000) | $(4,220,000) | $(6,895,000) |
| Cash & Equivalents (End of Period) | $838,000 | YTD Operating Cash Flow: $(4,601,000) | ||
| Working Capital | $(2,596,000) | Accumulated Deficit: $(301.5M) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 128% QoQ (vs. prior year) and 103% YTD, driven primarily by a $230,000 increase in LockeT sales. VIVO sales decreased slightly due to reduced commercial efforts in the EU.
- Expense Increases: Operating expenses rose significantly due to:
- Acquired IPR&D: $1.85 million expense in Q2 2025 (vs. $0 in Q2 2024) related to the Cardionomic asset acquisition (CPNS System) and Perikard acquisition.
- SG&A: Increased by $168,000 in Q2 due to higher salaries (headcount grew from 15 to 21) and stock-based compensation.
- R&D: Increased by $74,000 in Q2 due to new full-time R&D hires.
- Non-Cash Fair Value Adjustments: A $1.67 million loss was recorded for the change in fair value of royalties payable due to related parties, driven by a US patent grant for LockeT triggering additional royalty obligations.
- Financing Activity: The company raised capital via a May 2025 PIPE financing ($1.5M cash + debt securities) and an At-The-Market (ATM) offering ($1.7M gross proceeds YTD).
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for 12 months. Cash on hand ($0.8M) is insufficient to fund operations or repay short-term notes due in January 2026 without additional financing.
- Capital Needs: The company expects to require additional financing prior to the end of the current quarter. It is evaluating continued ATM sales and potential debt/equity transactions.
- Subsequent Event - Reverse Stock Split: On July 25, 2025, stockholders approved a 1-for-19 reverse stock split, effective August 15, 2025. This will reduce outstanding shares from ~18.9M to ~0.99M.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including lack of segregation of duties and inadequate review controls for financial reporting and tax provisions.
- Related Party Transactions: Significant debt and royalty obligations exist with the CEO and his affiliates, including $1.7M in related party notes and accrued interest.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and certainty of the next financing round given the "substantial doubt" disclosure and $1.7M in related party notes due Jan 2026.
- Reverse Stock Split Impact: Confirm the post-split share count and potential impact on liquidity and listing status on NYSE American.
- Royalty Obligations: Review the specific terms of the LockeT royalty agreements with related parties, particularly the impact of the new US patent on future cash outflows.
- IPR&D Utilization: Assess the commercial viability and regulatory timeline for the CPNS System (Cardionomix) and KardioNav technologies, as these represent significant recent expenses with no current revenue.
- Internal Control Remediation: Monitor the progress of the remediation plan for material weaknesses in financial reporting controls.